Diagnostic Oncology CRO will conduct research and clinical tests of Nu.Q NETs and Nu.Q blood tests to determine the test’s clinical utility for cancer and sepsis. The tests will be administered at several U.S. sites, according to the Aug. 8 VolitionRx news release.
“We’re delighted to be working with Volition, providing support and acting as the company’s regulatory and clinical affairs team in the U.S. Volition’s technology has the potential to significantly improve patient outcomes in those diagnosed with sepsis or cancer, said Diagnostic Oncology CRO CEO and President Thomas Soriano. “Through the conduct of Volition’s clinical validation studies, we hope to validate a broad range of potential Nu.Q products and support Volition’s U.S. commercialization strategy.”
